<DOC>
	<DOCNO>NCT00002917</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I/II trial study effectiveness paclitaxel treat patient early-stage bladder cancer .</brief_summary>
	<brief_title>Paclitaxel Treating Patients With Early-Stage Bladder Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate toxicity safety intravesical paclitaxel patient superficial bladder cancer . II . Evaluate efficacy paclitaxel transitional cell carcinoma situ ( CIS ) and/or unresectable papillary superficial bladder cancer . III . Evaluate dose-response effect choose appropriate dose clinical study . OUTLINE : Cohorts patient receive intravesical paclitaxel escalate dos , administer twice weekly 6 week , every 2 week another 6 week , maximum 2 course dose level . Patients must complete 8 first 15 instillation 3 month cystoscopic exam biopsy cytology deem evaluable . Participants follow quarterly cytoscopy cytology additional 21 month period . Biopsies perform 3 and/or 6 month , thereafter clinically applicable . PROJECTED ACCRUAL : 19 evaluable patient enrol .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven CIS and/or unresectable/residual superficial bladder tumor ( pTa G1G3 pT1 G1G3 ) confirm biopsy , bladder mapping , positive cytology Cystoscopic examination bladder mapping must perform within 6 week study PATIENT CHARACTERISTICS : Age : 18 Performance Status : Karnofsky 60 100 % Life Expectancy : Not specify Hematopoietic : Hemoglobin great 11 g/dL WBC great 4500/mm3 Neutrophils great 1500/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin , AST , ALT great 2.5 x normal Renal : Creatinine great 2.5 x normal Cardiovascular : No concurrent cardiovascular disease Other : No active infection require concurrent therapy Not pregnant nursing No upper renal tract disease No concurrent malignancy except basal squamous cell skin cancer noninvasive cancer cervix PRIOR CONCURRENT THERAPY : Biologic therapy : No intravesical BCG within 3 month prior study entry Prior BCG therapy require CIS patient ( contraindicate ) Chemotherapy : No prior intravesical chemotherapy within 4 week prior study No prior systemic anticancer therapy within 4 month prior study No prior paclitaxel therapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy within 4 month prior study Surgery : Not specify Other : No hypersensitivity reaction product contain cremophor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2001</verification_date>
	<keyword>stage 0 bladder cancer</keyword>
	<keyword>stage I bladder cancer</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
</DOC>